Ketamine as an adjuvant for the treatment of first episode depressio
Not Applicable
- Conditions
- Health Condition 1: F321- Major depressive disorder, singleepisode, moderateHealth Condition 2: F322- Major depressive disorder, singleepisode, severe without psychotic features
- Registration Number
- CTRI/2022/04/042071
- Lead Sponsor
- Ahana Hospitals LLP
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Participants willing to sign a written informed consent document;
Participants must fulfill ICD criteria for Depressive episode , with the severity being moderate to severe
Participants must be medically and neurologically healthy.
Exclusion Criteria
Those who have neurological disorders, severe medical illness, mental retardation and co-morbid psychiatric diagnoses
Women who are pregnancy or breastfeeding
Those who are allergic to ketamine
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hamilton Depression rating scale (HAM-D) to assess severity of depressionTimepoint: baseline, day 2, day 14
- Secondary Outcome Measures
Name Time Method Beck Scale for Suicidal Ideation (BSSI) to assess the level of suicidal ideationTimepoint: baseline, day 2 and day 14